Portal de Periódicos da CAPES

An alternative method to dithiothreitol treatment for antibody screening in patients receiving daratumumab

2015; Wiley; Volume: 55; Issue: 9 Linguagem: Inglês

10.1111/trf.13174

1537-2995

Amy E. Schmidt, Scott A. Kirkley, Nisha Patel, Debra Masel, Renee Bowen, Neil Blumberg, Majed A. Refaai,

Immune Cell Function and Interaction

TransfusionVolume 55, Issue 9 p. 2292-2293 LETTERS TO THE EDITOR An alternative method to dithiothreitol treatment for antibody screening in patients receiving daratumumab Amy E. Schmidt MD, PhD, Corresponding Author Amy E. Schmidt MD, PhD Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NYe-mail: [email protected]Search for more papers by this authorScott Kirkley MD, Scott Kirkley MD Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NYSearch for more papers by this authorNisha Patel MD, Nisha Patel MD Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NYSearch for more papers by this authorDebra Masel MT(ASCP)SBB, Debra Masel MT(ASCP)SBB Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NYSearch for more papers by this authorRenee Bowen MT(ASCP), Renee Bowen MT(ASCP) Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NYSearch for more papers by this authorNeil Blumberg MD, Neil Blumberg MD Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NYSearch for more papers by this authorMajed A. Refaai MD, Majed A. Refaai MD Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NYSearch for more papers by this author Amy E. Schmidt MD, PhD, Corresponding Author Amy E. Schmidt MD, PhD Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NYe-mail: [email protected]Search for more papers by this authorScott Kirkley MD, Scott Kirkley MD Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NYSearch for more papers by this authorNisha Patel MD, Nisha Patel MD Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NYSearch for more papers by this authorDebra Masel MT(ASCP)SBB, Debra Masel MT(ASCP)SBB Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NYSearch for more papers by this authorRenee Bowen MT(ASCP), Renee Bowen MT(ASCP) Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NYSearch for more papers by this authorNeil Blumberg MD, Neil Blumberg MD Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NYSearch for more papers by this authorMajed A. Refaai MD, Majed A. Refaai MD Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NYSearch for more papers by this author First published: 15 September 2015 https://doi.org/10.1111/trf.13174Citations: 35Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. REFERENCES 1 Chapuy CI, Nicholson RT, Aguad MD, et al . Resolving the daratumumab interference with blood compatibility testing. Transfusion 2015; 55: 1545-54. Google Scholar 2 Khagi Y, Mark TM. Potential role of daratumumab in the treatment of multiple myeloma. Onco Targets Ther 2014; 7: 1095-100. PubMedWeb of Science®Google Scholar 3 Deaglio S, Mehta K, Malavasi F. Human CD38: a (r)evolutionary story of enzymes and receptors. Leuk Res 2001; 25: 1-12. 10.1016/S0145-2126(00)00093-X CASPubMedWeb of Science®Google Scholar 4 Malavasi F, Deaglio S, Funaro A, et al. Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology. Physiol Rev 2008; 88: 841-86. 10.1152/physrev.00035.2007 CASPubMedWeb of Science®Google Scholar 5 Plesner T, Lokhorst HM, Gimsing P, et al. Daratumumab, a CD38 monoclonal antibody in patients with multiple myeloma—data from a dose-escalation phase I/II study. 54th ASH annual meeting and exposition abstracts book; 2012 Dec 8-11; Atlanta, GA. Google Scholar Citing Literature Volume55, Issue9September 2015Pages 2292-2293 ReferencesRelatedInformation